SYGNIS Launches TruePrime Liquid Biopsy Kit Targeting Oncology Research And Diagnostics
- Selective amplification of circulating tumor DNA
- Valuable oncology research tool
- Strong diagnostic potential for early stage tumors and tumor monitoring
- Targeting fast growing, multi-billion dollar markets
- Additional patent application filed
Madrid, Spain, and Heidelberg, Germany, November 16, 2016 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the launch of its TruePrimeTM Liquid Biopsy Kit, a ready to use amplification kit for ct-DNA (circulating tumor DNA), to be used in the detection, analysis and monitoring of early tumor stages.
Liquid biopsy, the analysis of tumor-derived DNA traces in the blood of a patient, has the potential to revolutionize diagnostic medicine, particularly in oncology. Current techniques for cell-free DNA (cf-DNA) analysis are limited due to a lack of sensitivity. These limitations are inherently linked with the low abundance of ct-DNA present in bodily fluid samples, particularly when such samples are to be analysed by next generation sequencing (NGS).
Whilst the underlying technology for the TruePrimeTM technology is already covered by granted patents in several jurisdictions and additional patent application to protect this very commercially attractive application has recently been submitted.
In addition to becoming a valuable tool in oncology research this technology will also have utility in the field of precise medicine and has the potential to take up a piviotal role in the diagnosis and monitoring of cancer. The last ten years have seen enormous progress in both the understanding of cancer disease as well as the development of targeted therapies. Liquid biopsy is one of the fastest developing areas in this field, with a huge potential to revolutionize diagnostic medicine. Estimations for the global liquid biopsy market in 2020 range upwards from a conservative $1.3 billion. SYGNIS’s TruePrimeTM Liquid Biopsy technology is well positioned to take a central role in the highly valuable market segment.
Heikki Lanckriet co-CEO and CSO of SYGNIS commented: “TruePrimeTM Liquid Biopsy is unique in that it selectively amplifies cancerous DNA in blood samples. Moreover the TruePrimeTM DNA amplification technology provides higher quality DNA as it amplifies more accurately with less bias than any other DNA amplification technology currently available. It is also 1000 times more sensitive than any other multiple displacement amplification (MDA) technique currently availableon the market. Due to these valuable properties the technology is poised to make a momentous impact in the field of oncology research and cancer diagnosis.”
- Valuable oncology research tool
- Strong diagnostic potential for early stage tumors and tumor monitoring
- Targeting fast growing, multi-billion dollar markets
- Additional patent application filed
Madrid, Spain, and Heidelberg, Germany, November 16, 2016 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the launch of its TruePrimeTM Liquid Biopsy Kit, a ready to use amplification kit for ct-DNA (circulating tumor DNA), to be used in the detection, analysis and monitoring of early tumor stages.
Liquid biopsy, the analysis of tumor-derived DNA traces in the blood of a patient, has the potential to revolutionize diagnostic medicine, particularly in oncology. Current techniques for cell-free DNA (cf-DNA) analysis are limited due to a lack of sensitivity. These limitations are inherently linked with the low abundance of ct-DNA present in bodily fluid samples, particularly when such samples are to be analysed by next generation sequencing (NGS).
Whilst the underlying technology for the TruePrimeTM technology is already covered by granted patents in several jurisdictions and additional patent application to protect this very commercially attractive application has recently been submitted.
In addition to becoming a valuable tool in oncology research this technology will also have utility in the field of precise medicine and has the potential to take up a piviotal role in the diagnosis and monitoring of cancer. The last ten years have seen enormous progress in both the understanding of cancer disease as well as the development of targeted therapies. Liquid biopsy is one of the fastest developing areas in this field, with a huge potential to revolutionize diagnostic medicine. Estimations for the global liquid biopsy market in 2020 range upwards from a conservative $1.3 billion. SYGNIS’s TruePrimeTM Liquid Biopsy technology is well positioned to take a central role in the highly valuable market segment.
Heikki Lanckriet co-CEO and CSO of SYGNIS commented: “TruePrimeTM Liquid Biopsy is unique in that it selectively amplifies cancerous DNA in blood samples. Moreover the TruePrimeTM DNA amplification technology provides higher quality DNA as it amplifies more accurately with less bias than any other DNA amplification technology currently available. It is also 1000 times more sensitive than any other multiple displacement amplification (MDA) technique currently availableon the market. Due to these valuable properties the technology is poised to make a momentous impact in the field of oncology research and cancer diagnosis.”